In addition, there were lower levels of the differentiation related TFs and higher levels of expression of JUN, IRF1, JUNB, and FOSL2 observed in melanomas with no BRAF mutational resistance mechanisms (normalised to patient matched pre-treatment tumours), compared to melanomas containing BRAF mutational resistance mechanisms (Figure S7B). This evidence concerns the gene IRF1 and melanoma.